MilliporeSigma launches VirusExpress® 293 adeno-associated virus production platform
by CM Staff
The new platform is an extension of the company's VirusExpress® offering, which can potentially help reduce process development time up to 40 percent.
MilliporeSigma scientists operating a 200 L Mobius® Single-Use Bioreactor using the VirusExpress® 293 Adeno-Associated Virus Production Platform at the company’s facility in Carlsbad, California.
BURLINGTON — MilliporeSigma has launched the VirusExpress® 293 Adeno-Associated Virus Production Platform, a viral vector manufacturing offering that includes AAV, Lentiviral, CDMO, CTO, and process development.
This new platform enables biopharmaceutical companies to increase the speed to clinical manufacturing while reducing process development time and costs.
“Cell and gene therapies offer the potential for curative treatments and can be commercialized in half the time compared to traditional therapies,” said Dirk Lange, head of life science services, life science business sector of Merck KGaA, Darmstadt, Germany.
“By increasing dose yields and dramatically reducing process development time, our VirusExpress® 293 AAV Production Platform will accelerate manufacturing of these therapies, ultimately delivering lifesaving treatments to patients faster.”
The new platform is an extension of the company’s VirusExpress® offering, which can potentially help reduce process development time up to 40 percent.
The company’s VirusExpress® Lentiviral Production Platform is designed to help users increase the speed to clinical manufacturing, and ultimately help transition a legacy process to a templated solution.
